Johnson & Johnson Covid-19 vaccine is 66% effective in global trial | Editorji
  1. home
  2. > covid-19
  3. > Johnson & Johnson Covid-19 vaccine is 66% effective in global trial
replay trump newslist
up NEXT IN 5 SECONDS sports newslist
tap to unmute
00:00/00:00
NaN/0

Johnson & Johnson Covid-19 vaccine is 66% effective in global trial

Jan 29, 2021 23:38 IST

Johnson & Johnson said on Friday that its single-dose vaccine was 66 per cent effective in preventing COVID-19 in a large global trial against multiple variants. In the trial of nearly 44,000 volunteers, the level of protection against moderate and severe COVID-19 varied from 72 per cent in the United States, to 66 per cent in Latin America and just 57 per cent in South Africa, from where a worrying variant has spread. J&J's main goal was the prevention of moderate to severe COVID-19, and the vaccine was 85 per cent effective in stopping severe disease and preventing hospitalization across all geographies and against multiple variants 28 days after immunization.

Covid-19